Latest Articles

Publication Date
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
Establishment and Characterization of a New Immortalized Human Adenomyosis Epithelial-Like Cell Line, tAEC21†.

Adenomyosis occurs when endometrial glands and stroma grow within the uterine myometrium. As a clinically significant disease, adenomyosis causes substantial pelvic pain and heavy menstrual bleeding. It remains understudied due …

Published: Nov. 20, 2025, midnight
Adenomyosis in patients with rheumatic diseases: a cross-disciplinary clinical observation.

Autoimmune and inflammatory rheumatic diseases (RDs) are more prevalent in women and often affect gynecological health. Particularly, heavy menstrual bleeding (HMB) and dysmenorrhea are more common in patients with RD. …

Published: Nov. 18, 2025, midnight
Cannabidiol and ∆9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms.

Endometriosis is a chronic, inflammatory, and multifactorial disease characterized by the presence of endometrial tissue outside the uterine cavity, often associated with debilitating symptoms. It affects approximately 10% of women …

Published: Nov. 17, 2025, midnight
''Non-Invasive Extracellular Vesicle Biomarkers in Endometriosis, Molecular Signatures Linking Pelvic Inflammation, Oocyte Quality, and IVF Outcomes''.

Endometriosis impairs fertility by interfering with ovarian function, embryonic development, and endometrial receptivity. Extracellular vesicles (EVs) are recognised as non-invasive biomarkers that may indicate biological processes based on their lipid, …

Published: Nov. 17, 2025, midnight
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech

Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech

Published: Nov. 13, 2025, 9 a.m.
Assessing Uterine Fibroid Symptoms and Health-related Quality of Life among women at Korle Bu Teaching Hospital, Ghana: an analytical cross-sectional study using the UFS-QoL questionnaire.

Uterine fibroids are highly prevalent and constitute significant health and social concerns, particularly among black-African women of reproductive age. However, beyond the clinical burden, there is limited data on the …

Published: Nov. 12, 2025, midnight
Early and delayed post-cesarean complications: an imaging review.

Cesarean delivery is a common procedure, currently accounting for one-third of live births in the US. In the acute post-operative setting, it can be difficult to distinguish changes of the …

Published: Nov. 11, 2025, midnight
Deciphering the relationship between adenomyosis and the microbiota: a systematic review.

Adenomyosis is a benign displacement of endomerial tissue into the uterine myometrium, the exact pathogenesis of which has not yet been established. Recently, there has been increased research on the …

Published: Nov. 11, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!